Viking Therapeutics, Inc. (VKTX)

Market Cap	3.80B
Revenue (ttm)	n/a
Net Income (ttm)	-109.96M
Shares Out	111.57M
EPS (ttm)	-1.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,664,429
Open	31.83
Previous Close	31.63
Day's Range	31.50 - 36.39
52-Week Range	28.64 - 99.41
Beta	0.89
Analysts	Strong Buy
Price Target	97.29 (+185.56%)
Earnings Date	Feb 5, 2025

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2015
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: VKTX
• Website: https://www.vikingtherapeutics.com

Analyst Forecast

According to 14 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price forecast is $97.29, which is an increase of 185.56% from the latest price.

Price Target

$97.29

(185.56% upside)

Analyst Consensus: Strong Buy